345 related articles for article (PubMed ID: 1879447)
41. General principles and perspectives of cancer therapy with radiopharmaceuticals.
Shapiro B; Fig LM
J Nucl Med Allied Sci; 1990; 34(4):260-4. PubMed ID: 2090790
[No Abstract] [Full Text] [Related]
42. Which radionuclides will nuclear oncology need tomorrow?
Barbet J; Chatal JF; Gauché F; Martino J
Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):627-30. PubMed ID: 16741760
[No Abstract] [Full Text] [Related]
43. Specific targeting of cancer with monoclonal antibodies. Diagnostic and therapeutic applications.
Abrams PG
Front Radiat Ther Oncol; 1990; 24():182-5; discussion 202-3. PubMed ID: 2187757
[No Abstract] [Full Text] [Related]
44. Effect of tumour shrinkage on the biological effectiveness of permanent brachytherapy implants.
Dale RG; Jones B; Coles IP
Br J Radiol; 1994 Jul; 67(799):639-45. PubMed ID: 8061998
[TBL] [Abstract][Full Text] [Related]
45. Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium.
Rubini G; Nicoletti A; Rubini D; Asabella AN
Cancer Biother Radiopharm; 2014 Feb; 29(1):1-11. PubMed ID: 24180669
[TBL] [Abstract][Full Text] [Related]
46. [New radiopharmaceuticals for oncologic diagnosis and therapy: developments in radioimmunoscintigraphy and radioimmunotherapy].
Eisenhut M; Brandau W; Reinel U; Kimmig B
Rontgenblatter; 1989 Jan; 42(1):24-7. PubMed ID: 2645635
[TBL] [Abstract][Full Text] [Related]
47. Monoclonal antibodies: old and new trends in breast cancer imaging and therapeutic approach.
Stipsanelli E; Valsamaki P
Hell J Nucl Med; 2005; 8(2):103-8. PubMed ID: 16142251
[TBL] [Abstract][Full Text] [Related]
48. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.
de Visser M; Verwijnen SM; de Jong M
Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684
[TBL] [Abstract][Full Text] [Related]
49. Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapy.
Ting G; Chang CH; Wang HE; Lee TW
J Biomed Biotechnol; 2010; 2010():. PubMed ID: 20811605
[TBL] [Abstract][Full Text] [Related]
50. Peptide receptor radionuclide therapy: an overview.
Dash A; Chakraborty S; Pillai MR; Knapp FF
Cancer Biother Radiopharm; 2015 Mar; 30(2):47-71. PubMed ID: 25710506
[TBL] [Abstract][Full Text] [Related]
51. [Radionuclides, technologies and quality control in brachytherapy].
Marchesi V; Gautier M; Villani N; Feuillade J; Dejean C
Cancer Radiother; 2013 Apr; 17(2):85-8. PubMed ID: 23474213
[TBL] [Abstract][Full Text] [Related]
52. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019.
Lee WR; Bae K; Lawton C; Gillin M; Morton G; Firat S; Baikadi M; Kuettel M; Greven K; Sandler H
Cancer; 2007 Apr; 109(8):1506-12. PubMed ID: 17340591
[TBL] [Abstract][Full Text] [Related]
53. Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide.
Ellis RJ; Zhou H; Kim EY; Fu P; Kaminsky DA; Sodee B; Colussi V; Vance WZ; Spirnak JP; Kim C; Resnick MI
Brachytherapy; 2007; 6(1):16-25. PubMed ID: 17284381
[TBL] [Abstract][Full Text] [Related]
54. A comparison of the impact of isotope ((125)I vs. (103)Pd) on toxicity and biochemical outcome after interstitial brachytherapy and external beam radiation therapy for clinically localized prostate cancer.
Kollmeier MA; Pei X; Algur E; Yamada Y; Cox BW; Cohen GN; Zaider M; Zelefsky MJ
Brachytherapy; 2012; 11(4):271-6. PubMed ID: 22192495
[TBL] [Abstract][Full Text] [Related]
55. Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects.
Bhardwaj R; van der Meer A; Das SK; de Bruin M; Gascon J; Wolterbeek HT; Denkova AG; Serra-Crespo P
Sci Rep; 2017 Mar; 7():44242. PubMed ID: 28287131
[No Abstract] [Full Text] [Related]
56. Targeted therapy using alpha emitters.
Vaidyanathan G; Zalutsky MR
Phys Med Biol; 1996 Oct; 41(10):1915-31. PubMed ID: 8912371
[TBL] [Abstract][Full Text] [Related]
57. Radionuclides in radiation-induced bystander effect; may it share in radionuclide therapy?
Widel M
Neoplasma; 2017; 64(5):641-654. PubMed ID: 28592116
[TBL] [Abstract][Full Text] [Related]
58. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
Lee HK; Adams MT; Motta J
Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939
[TBL] [Abstract][Full Text] [Related]
59. Therapeutic radionuclides: production and decay property considerations.
Volkert WA; Goeckeler WF; Ehrhardt GJ; Ketring AR
J Nucl Med; 1991 Jan; 32(1):174-85. PubMed ID: 1988628
[TBL] [Abstract][Full Text] [Related]
60. Technological advances in radioimmunotherapy.
Dearling JL; Pedley RB
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):457-69. PubMed ID: 17537620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
